Vir Biotechnology Stock News

--Company to Host Conference Call on Tuesday, December 7, 2021, at 8:30 am ET-- --Company to Host Conference Call on Tuesday, December 7, 2021, at 8:30 am ET--

GlaxoSmithKline plc (NYSE: GSK) said that its antibody-based COVID-19 therapy with U.S. partner Vir Biotechnology Inc (NASDAQ: VIR) is effective against all mutations of the new Omicron coronaviru

GSK Singapore is contracted to supply the Government of Singapore with additional doses of sotrovimab, following the first purchase placed by the Ministry of Health (MOH) in June 2021 Sotrovimab was approved by the Singapore Health Sciences Authority (HSA) under the Pandemic Special Access Route (PSAR) for interim authorization in June 2021 SINGAPORE , Dec. 7, 2021 /PRNewswire/ -- GlaxoSmithKline Singapore announced an agreement with the Government of Singapore to supply additional doses of sotrovimab. Sotrovimab is an investigational single-dose monoclonal antibody developed in partnership with Vir Biotechnology, for the treatment of patients with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19. This follows the initial purchase agreement signed between GSK Singapore and the government in June 2021 . Priya Kudva Menon , VP and General Manager, GSK Singapore, said: "As we move into the endemic stage of COVID-19 in Singapore , it is clear that multiple treatment options are needed to manage the impact of this virus on people and communities, in addition to vaccinations and other preventative measures.

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Herbert Virgin sold 15,125 shares of the businesss stock in a transaction dated Tuesday, November 30th. The stock was sold at an average price of $49.60, for a total value of $750,200.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. []

Baillie Gifford & Co. lifted its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 1.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,899,692 shares of the companys stock after buying an additional 50,183 shares during the quarter. []

Glaxo (GSK) and Vir Biotechnology announce promising pre-clinical data from the study of their antibody candidate, sotrovimab, against mutations found in the Omicron variant.

London, Dec 3 (IANS) British drugmaker GlaxoSmithKline has claimed that early laboratory tests show that its antibody drug against Covid-19 is effective against the new super mutant Omicron variant. GSK developed Sotrovimab, with US partner Vir Biotechnology, a monoclonal antibody based on the natural antibodies humans already make. In clinical trials, sotrovimab was shown to [] The post GSKs early data shows Covid antibody drug effective against Omicron appeared first on Buziness Bytes .

Related Stocks: VIR ,

A Covid-19 antibody treatment developed by GlaxoSmithKline and Vir Biotechnology was effective against the Omicron variant in early laboratory studies.

Developed by GSK and Vir Biotechnology, sotrovimab is a single monoclonal antibody and the drug works by binding to the spike protein on the outside of the Covid-19 virus, preventing the virus from attaching to and entering human cells, so that it cannot replicate in the body.

Futures Rebound Fizzles On Slowing iPhone Demand, Omicron Fears U.S. index futures regained some ground alongside Asian markets while European stocks slumped to session lows in a delayed response to yesterday''s late Omicron-driven US selloff, as markets remained volatile following the biggest two-day plunge in more than a year, spurred by concern about the omicron coronavirus variant and Federal Reserve tightening. Investors await data for unemployment claims, as well as earnings from companies including Dollar General and Kroger. Tech is the weakest sector, dropping in sympathy after Apple warned its suppliers of slowing iPhone demand. Nasdaq futures pared earlier gains of up to 0.8% to trade down 0.1% while S&P futures are only 0.2% higher after rising as much as 0.9%. While the knee-jerk reaction of stock investors may continue to be to take profits before the end of the year, there is plenty of liquidity available to drive stock prices higher as dip-buyers enter the market , Ed Yardeni wrote in a note.

In last trading session, Vir Biotechnology Inc. (NASDAQ:VIR) saw 3.52 million shares changing hands with its beta currently measuring 0. Companys recent per share price level of $46.97 trading at -$0.45 or -0.95% at ring of the bell on the day assigns it a market valuation of $5.95B. That closing price of VIRs stock is After A 50.40% Jump This Year Is Vir Biotechnology Inc. (NASDAQ:VIR) A Better Buy Than Others? Read More »

LONDON: British regulators on Thursday approved a GlaxoSmithKline drug to treat those at high risk of developing severe Covid-19 symptoms, with the manufacturer saying it appears effective against the new Omicron variant. The antibody treatment, sotrovimab, "was found to be safe and effective at reducing the risk of hospitalisation and death in people with mild to moderate COVID-19 infection who are at an increased risk of developing severe disease," said the Medicines and Healthcare products Regulatory Agency (MHRA). Preclinical data showed that the drug "retains activity against key mutations of the new Omicron SARS-CoV-2 variant," GlaxoSmithKline (GSK) said in a statement. First known UAE case of Omicron variant detected in fully vaccinated traveller "To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO)," it added. Testing is ongoing "to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021." A single dose of the drug was found to reduce the risk of hospitalisation and death by 79 percent in high-risk adults with symptomatic COVID-19 infection, according to the MHRA.

The stock price of Vir Biotechnology Inc (NASDAQ: VIR) increased by over 20% pre-market today. This is why it happened.

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced an update to bioRxiv, a preprint server, with preclinical data for sotrovimab, COVID-19 targeting monoclonal